RT Journal Article
SR Electronic
T1 Evidence of lesions from Epstein-Barr virus infection in human breast cancer genomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.24.24309410
DO 10.1101/2024.06.24.24309410
A1 Friedenson, Bernard
YR 2024
UL http://medrxiv.org/content/early/2024/06/26/2024.06.24.24309410.abstract
AB Epstein-Barr virus (EBV) infects essentially all humans and provides no benefit. EBV can cause nasopharyngeal cancer (NPC), Burkitt’s lymphoma (BL), and perhaps breast cancer. Breast tissues from patients with breast cancer are more likely to be EBV-positive than tissues from healthy controls. However, EBV is not a proven cause of breast cancer because the tissues are not consistently EBV-positive. If EBV causes breast cancer, it would have to do it without an active infection. Other cancers with known viral origins do not require continuing presence of the virus. However, the "hit and run" theory is difficult to test for breast cancer without a proven EBV connection.Here, I test this theory with multiple independent bioinformatic analyses. First, hundreds of breast cancer genomes contained characteristic methylation scars that indicate a cleared EBV infection. The genomes had further differential hypermethylation near positions where EBV reprograms normal cells into malignancy. Second, genomes from EBV cancers and breast cancers inactivated the same tumor-suppressive mechanisms. Third, deletions were identified on chromosome 3p in EBV cancers that shift cells to oxidative glycolysis, a prominent breast cancer phenotype known as the Warburg effect. Similar 3p deletions were found in breast cancer genomes. Fourth, somatic hypermutation clusters in EBV-cancers marked genome positions in breast cancers near translocations and focal oncogene amplification. EBV deregulation of deaminase and estrogen-induced topoisomerase explain these translocation breakpoints. Fifth, several alternate explanations for these results were ruled out. Finally, only limited segments of EBV DNA matched the human genome, making it possible that a childhood vaccine would end breast cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:www.nature.com https://www.nature.com/articles/s41467-021-24348-6 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428665/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors